5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 16.62▼ | 16.62▼ | 16.66▼ | 17.16▼ | 16.53▼ |
MA10 | 16.64▼ | 16.70▼ | 16.84▼ | 17.22▼ | 15.41▲ |
MA20 | 16.64▼ | 16.91▼ | 17.10▼ | 16.47▲ | 15.01▲ |
MA50 | 16.71▼ | 17.17▼ | 17.33▼ | 15.24▲ | 12.86▲ |
MA100 | 16.87▼ | 17.33▼ | 16.72▼ | 14.87▲ | 9.37▲ |
MA200 | 17.12▼ | 16.67▼ | 15.67▲ | 13.92▲ | 13.79▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.005▼ | -0.025▼ | -0.068▼ | -0.026▼ | 0.137▲ |
RSI | 36.777▼ | 27.932▼ | 27.805▼ | 53.307▲ | 56.643▲ |
STOCH | 56.963 | 13.562▼ | 8.235▼ | 64.172 | 73.981 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -58.448 | -28.974 |
CCI | -192.827▼ | -122.786▼ | -115.397▼ | -5.833 | 135.741▲ |
Friday, September 05, 2025 01:57 PM
Despite volatility and regulatory headwinds, AMT-130's efficacy and safety profile could position it as a first-in-class, disease-modifying therapy with blockbuster potential. Read on here.
|
Friday, September 05, 2025 07:35 AM
Qure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy.
|
Friday, September 05, 2025 04:22 AM
AMSTERDAM, Sept. 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transforma ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
12/09/25 | 16.85 | 17.189 | 16.48 | 16.485 | 670,990 |
11/09/25 | 17.61 | 17.755 | 16.69 | 16.94 | 765,472 |
10/09/25 | 17.49 | 17.55 | 17.26 | 17.48 | 821,688 |
09/09/25 | 17.52 | 17.76 | 17.03 | 17.49 | 819,900 |
08/09/25 | 18.16 | 18.17 | 17.21 | 17.43 | 1,386,278 |
05/09/25 | 17.92 | 18.18 | 17.37 | 17.95 | 2,079,770 |
04/09/25 | 17.37 | 17.79 | 16.5603 | 17.73 | 976,924 |
03/09/25 | 17.25 | 17.6548 | 16.85 | 17.38 | 1,475,165 |
02/09/25 | 16.28 | 17.135 | 16.08 | 17.01 | 1,198,284 |
29/08/25 | 16.27 | 16.36 | 15.59 | 16.33 | 711,243 |
|
|
||||
|
|
||||
|
|